Isolation and characterization of a human monoclonal antibody that recognizes epitopes shared by Pseudomonas aeruginosa immunotype 1, 3, 4, and 6 lipopolysaccharides

A hybridoma line secreting a human monoclonal antibody (HMAb) capable of recognizing Fisher immunotype (IT) 1, 3, 4, and 6 lipopolysaccharide (LPS) in vitro was isolated. Peripheral blood lymphocytes (PBL) were obtained from volunteers immunized with an experimental Pseudomonas aeruginosa O polysaccharide-toxin A vaccine. PBL-expressing surface antibodies able to bind to P. aeruginosa LPS were isolated by adsorption onto LPS-coated plastic wells. Such PBL were transformed with Epstein-Barr virus. Lymphoblastoid cell lines secreting anti-P. aeruginosa LPS antibodies were identified by an enzyme-linked immunosorbent assay and fused to the F3B6 heteromyeloma line. A hybridoma line producing a HMAb (2-8AH79) able to bind IT-1, IT-3, IT-4, and IT-6 LPS was identified by an enzyme-linked immunosorbent assay. This HMAb was found to bind to the O-polysaccharide regions of IT-1, IT-3, IT-4, and IT-6 LPS, as determined by immunoblotting. By using an immunofluorescence microscopy assay, the cell surfaces of IT-3 and IT-4 bacteria were strongly stained by HMAb 2-8AH79, whereas those of IT-1 and IT-6 bacteria were weakly stained. This HMAb was found to promote the uptake and killing of IT-3 and IT-4 bacteria, but not IT-1 or IT-6 organisms, by human polymorphonuclear leukocytes. Similarly, the passive transfer of HMAb 2-8AH79 to mice afforded significant protection only against a challenge with IT-3 and IT-4 bacteria.

[1]  N. Sigal,et al.  Human monoclonal antibodies that protect mice against challenge with Pseudomonas aeruginosa , 1988, Infection and immunity.

[2]  D. Lombardo HumanMonoclonal Antibodies ThatProtect Miceagainst Challenge withPseudomonas aeruginosa , 1988 .

[3]  B. Lânyi,et al.  The structure of O-specific polysaccharides and serological classification of Pseudomonas aeruginosa (a review). , 1988, Acta microbiologica Hungarica.

[4]  Y. Masuho,et al.  Immunoprotective human monoclonal antibodies against five major serotypes of Pseudomonas aeruginosa. , 1987, Journal of general microbiology.

[5]  A. Cross,et al.  Safety and immunogenicity of a Pseudomonas aeruginosa O-polysaccharide toxin A conjugate vaccine in humans. , 1987, The Journal of clinical investigation.

[6]  S. Cryz,et al.  A polyvalent Pseudomonas aeruginosa O-polysaccharide-toxin A conjugate vaccine. , 1987, Antibiotics and chemotherapy.

[7]  Y. Masuho,et al.  Characterization of a human monoclonal antibody to lipopolysaccharides of Pseudomonas aeruginosa serotype 5: a possible candidate as an immunotherapeutic agent for infections with P. aeruginosa. , 1985, The Journal of infectious diseases.

[8]  J. Larrick,et al.  In Vitro Expansion of Human B Cells for the Production of Human Monoclonal Antibodies , 1985 .

[9]  E. Engleman,et al.  Rescue of human monoclonal antibody production from an EBV-transformed B cell line by fusion to a human-mouse hybridoma. , 1984, Journal of immunological methods.

[10]  T. Pitt,et al.  Role of lipopolysaccharide in virulence of Pseudomonas aeruginosa , 1984, Infection and immunity.

[11]  M. Collins,et al.  Protective activity of an intravenous immune globulin (human) enriched in antibody against lipopolysaccharide antigens of Pseudomonas aeruginosa. , 1984, The American journal of medicine.

[12]  S. Wilkinson Composition and structure of lipopolysaccharides from Pseudomonas aeruginosa. , 1983, Reviews of infectious diseases.

[13]  C S Bryan,et al.  Analysis of 1,186 episodes of gram-negative bacteremia in non-university hospitals: the effects of antimicrobial therapy. , 1983, Reviews of infectious diseases.

[14]  S. Cryz,et al.  Protection against Pseudomonas aeruginosa infection in a murine burn wound sepsis model by passive transfer of antitoxin A, antielastase, and antilipopolysaccharide , 1983, Infection and immunity.

[15]  G. Bodey,et al.  Infections caused by Pseudomonas aeruginosa. , 1983, Reviews of infectious diseases.

[16]  G. Pier,et al.  Lipopolysaccharide and high-molecular-weight polysaccharide serotypes of Pseudomonas aeruginosa. , 1982, The Journal of infectious diseases.

[17]  T. Gootz,et al.  Resistance to cefamandole: a collaborative study of emerging clinical problems. , 1982, The Journal of infectious diseases.

[18]  C. Frasch,et al.  A sensitive silver stain for detecting lipopolysaccharides in polyacrylamide gels. , 1982, Analytical biochemistry.

[19]  J. Pennington,et al.  Type-specific vs. cross-protective vaccination for gram-negative bacterial pneumonia. , 1981, The Journal of infectious diseases.

[20]  R. J. Jones,et al.  CONTROLLED TRIAL OF PSEUDOMONAS IMMUNOGLOBULIN AND VACCINE IN BURN PATIENTS , 1980, The Lancet.

[21]  H. Towbin,et al.  Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. , 1979, Proceedings of the National Academy of Sciences of the United States of America.

[22]  G. Pier,et al.  Protective immunity induced in mice by immunization with high-molecular-weight polysaccharide from Pseudomonas aeruginosa , 1978, Infection and immunity.

[23]  M. Finland,et al.  Bacteremia at Boston City Hospital: Occurrence and mortality during 12 selected years (1935-1972), with special reference to hospital-acquired cases. , 1975, The Journal of infectious diseases.

[24]  I. A. Holder,et al.  Experimental studies of the pathogenesis of infections due to Pseudomonas aeruginosa: description of a burned mouse model. , 1975, The Journal of infectious diseases.

[25]  J. Wesley,et al.  Immunization against Pseudomonas in infection after thermal injury. , 1974, The Journal of infectious diseases.

[26]  L. Young,et al.  Pseudomonas aeruginosa infections. , 2008, CRC critical reviews in clinical laboratory sciences.

[27]  U. K. Laemmli,et al.  Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4 , 1970, Nature.

[28]  L. Reed,et al.  A SIMPLE METHOD OF ESTIMATING FIFTY PER CENT ENDPOINTS , 1938 .